Drug repurposing: In-vitro anti-glycation properties of 18 common drugs.

about

Drug repurposing: In-vitro anti-glycation properties of 18 common drugs.

Item

http://www.wikidata.org/entity/Q47232839

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Drug repurposing: In-vitro anti-glycation properties of 18 common drugs.

@en

Drug repurposing: In-vitro anti-glycation properties of 18 common drugs.

@nl

type

Item

label

Drug repurposing: In-vitro anti-glycation properties of 18 common drugs.

@en

Drug repurposing: In-vitro anti-glycation properties of 18 common drugs.

@nl

prefLabel

Drug repurposing: In-vitro anti-glycation properties of 18 common drugs.

@en

Drug repurposing: In-vitro anti-glycation properties of 18 common drugs.

@nl

P1476

Drug repurposing: In-vitro anti-glycation properties of 18 common drugs.

@en

P2093

Saima Rasheed

http://www.w3.org/2001/XMLSchema#string

Sammer Yousuf

http://www.w3.org/2001/XMLSchema#string

Sara S Sánchez

http://www.w3.org/2001/XMLSchema#string

Stella M Honoré

http://www.w3.org/2001/XMLSchema#string

P2860

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease

Discovery of rifampicin as a new anti-glycating compound by matrix-assisted laser desorption/ionization mass spectrometry-based insulin glycation assay.

Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products.

Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks.

Pyridoxine in clinical toxicology: a review.

Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug.

Glycoxidation of biological macromolecules: a critical approach to halt the menace of glycation.

Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds.

Global estimates of diabetes prevalence for 2013 and projections for 2035.

D-penicillamine: chemistry and clinical use in rheumatic disease.

P304

e0190509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0190509

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

M. Iqbal Choudhary

P577

2018-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29300762

http://www.w3.org/2001/XMLSchema#string

P932

5754062

http://www.w3.org/2001/XMLSchema#string